H. Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing ...

Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. and its board of directors concerning the proposed acquisition of the company by H. Lundbeck A/S ...

Baker McKenzie advise Lundbeck in $2.6B Longboard Pharmaceuticals acquisition.

Find insight on Gynesonics, Longboard Pharmaceuticals, Merck and more in the latest Market Talks covering Health Care.

Wall Street rolled to more records Monday as U.S. stocks added to their all-time highs. The Standard & Poor’s 500 index ...

Recent health briefs cover WHO's approval of Bavarian Nordic's mpox vaccine for adolescents, funding pledges for WHO's budget ...

The longboarding event in Abu Dhabi certainly had its moments. But, holding an event in this part of the world comes with ...

Lundbeck announced Monday it would buy Longboard Pharmaceuticals in a $2.6 billion deal that sent Longboard stock to a record ...

U.S. stocks rising Monday to add to their all-time highs. The S&P 500 was up 0.8% in afternoon trading and building on its ...